The reversal agent for dabigatran (Idarucizumab, Praxbind) can quickly halt the effect of the novel oral anticoagulant in patients with life threatening bleeding or in those who need urgent surgery, the final data from REVERSE-AD reveals. The findings confirm the results of an interim analysis that saw the reversal agent gain regulatory approval last year. ...
Dabigatran reversal agent stacks up in the real world
By Sunalie Silva
13 Jul 2017